Table 3 Overall results.
| Â | Â | No. of Subjects | Â | Â | Â | |
|---|---|---|---|---|---|---|
Model | No. of Contrasts | OMT | Control | Effect Size | 95% CI | P |
Median contrasts | Â | Â | Â | Â | Â | Â |
   Fixed-effects model* | 8 | 318 | 231 | -0.30 | -0.47 – -0.13 | .001 |
   Random-effects model | 8 | 318 | 231 | -0.31 | -0.49 – -0.13 | .001 |
Best-case scenario | 8 | 293 | 220 | -0.37 | -0.55 – -0.20 | <.001 |
Worst-case scenario | 8 | 298 | 221 | -0.18 | -0.35 – 0.00 | .046 |
Median contrasts, one OMT vs control treatment comparison per trial | Â | Â | Â | Â | Â | Â |
   Gibson [43] active treatment control and Licciardone [46] placebo control | 6 | 237 | 181 | -0.30 | -0.49 – -0.10 | .003 |
   Gibson [43] active treatment control and Licciardone [46] no treatment control | 6 | 247 | 179 | -0.39 | -0.59 – -0.20 | <.001 |
   Gibson [43] placebo control and Licciardone [46] placebo control | 6 | 238 | 187 | -0.26 | -0.45 – -0.06 | .01 |
   Gibson [43] placebo control and Licciardone [46] no treatment control | 6 | 248 | 185 | -0.35 | -0.54 – -0.15 | <.001 |
Median contrasts, Cleary [47] trial excluded | 7 | 310 | 227 | -0.29 | -0.47 – -0.12 | .001 |
All contrasts | 20 | 727 | 520 | -0.29 | -0.40 – -0.17 | <.001 |